Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's Why

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.73 and traded as low as $0.59. Vaxart shares last traded at $0.62, with a volume of 1,568,544 shares trading hands.

Vaxart Price Performance

The firm's fifty day moving average is $0.68 and its two-hundred day moving average is $0.73. The firm has a market capitalization of $140.95 million, a PE ratio of -1.51 and a beta of 0.62.

Institutional Trading of Vaxart

Hedge funds have recently added to or reduced their stakes in the stock. Mesirow Financial Investment Management Inc. grew its stake in shares of Vaxart by 100.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 20,000 shares during the period. XTX Topco Ltd raised its position in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 122,387 shares during the period. Geode Capital Management LLC lifted its stake in shares of Vaxart by 15.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock valued at $2,160,000 after buying an additional 346,725 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Vaxart in the 2nd quarter valued at approximately $402,000. Finally, Millennium Management LLC lifted its position in shares of Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company's stock worth $2,660,000 after acquiring an additional 2,095,274 shares in the last quarter. Institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.